Arglabin belongs to guaianolide class of sesquiterpene lactones, isolated from Artemisia species. The molecule bears a 5,7,5-tricyclic ring system having five contiguous stereo centers in which the two five membered rings are trans-annulated. Arglabin shows promising antitumor activity against different tumor cell lines. The antitumor activity of arglabin proceeds through its inhibition of farnesyl transferase which leads to the activation of RAS proto-oncogene, a process that is believed to play a pivotal role in 20-30% of all human tumors. It actually inhibits the incorporation of farnesyl pyrophosphate into human H-ras proteins by the enzyme farnesyl transferase (FTase). The present review is an attempt to summarize the chemistry and biology of this molecule since its isolation in 1982. It embodies the isolation, structure elucidation, stereo chemical description, structural classification, chemical synthesis, structural modifications and antitumor evaluation reported till date.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cbi.2015.08.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy.
Front Immunol
March 2025
Pfizer Oncology, Pfizer Inc., La Jolla, CA, United States.
Introduction: CD47 is highly expressed on cancer cells and triggers an anti-phagocytic "don't eat me" signal when bound by the inhibitory signal regulatory protein α (SIRPα) expressed on macrophages. While CD47 blockade can mitigate tumor growth, many CD47 blockers also bind to red blood cells (RBCs), leading to anemia. Maplirpacept (TTI-622, PF-07901801) is a CD47 blocking fusion protein consisting of a human SIRPα fused to an IgG4 Fc region and designed to limit binding to RBCs.
View Article and Find Full Text PDFSignificance of mouse xenograft tumor model using patient-derived cancer organoids for clinical drug development.
Front Oncol
February 2025
Department of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute, Osaka, Japan.
Background: and preclinical examinations of cancer cell lines are performed to determine the effectiveness of new drugs before initiating clinical trials. However, there is often a significant disparity between the promising results observed in preclinical evaluations and actual outcomes in clinical trials. Therefore, we hypothesized that this inconsistency might be due to the differences between the characteristics of cell lines and actual cancers in patients.
View Article and Find Full Text PDFThe Role of Crosslinking Agents in the Development of Collagen-Hydroxyapatite Composite Materials for Bone Tissue Engineering.
Materials (Basel)
February 2025
Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Chemical Engineering and Biotechnologies, National University of Science and Technology POLITEHNICA Bucharest, Gh. Polizu 1-7, 011061 Bucharest, Romania.
The lack of bone grafts represents a major issue in the orthopedic field, reconstructive surgery, and dentistry. There are several bone conditions that often demand the use of grafts, such as fractures, infections, and bone cancer. The number of bone cancer cases increased in the past few decades and along with it, the need for bone grafting materials.
View Article and Find Full Text PDFKinsenoside Suppresses DGAT1-Mediated Lipid Droplet Formation to Trigger Ferroptosis in Triple-Negative Breast Cancer.
Int J Mol Sci
March 2025
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Triple-negative breast cancer (TNBC) presents limited therapeutic options and is characterized by a poor prognosis. Although Kinsenoside (KIN) possesses a wide range of pharmacological activities, its effect and mechanism in TNBC remain unclear. The objective of this research was to explore the therapeutic effectiveness and the molecular mechanisms of KIN on TNBC.
View Article and Find Full Text PDFRevealing the Role of Beesioside O from for the Treatment of Breast Cancer Using Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation.
Int J Mol Sci
March 2025
State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100193, China.
Breast cancer remains a leading cause of malignancy-related mortality among women, with rising global incidence. While surgical intervention is effective for early-stage breast cancer, drug therapy is indispensable, particularly for triple-negative breast cancer, where treatment options are still limited. , a traditional Chinese medicinal herb, has been historically applied for inflammatory conditions, including pharyngitis and stomatitis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!